4
Clinical Trials associated with Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech)Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B Cell Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma
Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
100 Clinical Results associated with Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech)
100 Translational Medicine associated with Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech)
100 Patents (Medical) associated with Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech)
100 Deals associated with Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech)